ACRV
ACRV
NASDAQ · Biotechnology

Acrivon Therapeutics Inc

$1.47
+0.08 (+5.76%)
As of Apr 1, 3:35 PM ET ·
Financial Highlights (FY 2025)
Revenue
27.49M
Net Income
-6,413,122
Gross Margin
51.2%
Profit Margin
-23.3%
Rev Growth
+12.4%
D/E Ratio
0.29
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 51.2% 51.2% 51.2%
Operating Margin -26.8% -31.3% -30.1%
Profit Margin -23.3% -25.4% -27.4%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 27.49M 26.17M 29.17M
Gross Profit 14.08M 13.40M 14.94M
Operating Income -7,366,921 -8,203,916 -8,793,761
Net Income -6,413,122 -6,638,758 -7,979,028
Gross Margin 51.2% 51.2% 51.2%
Operating Margin -26.8% -31.3% -30.1%
Profit Margin -23.3% -25.4% -27.4%
Rev Growth +12.4% +6.3% +17.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 11.18M 10.69M 11.61M
Total Equity 38.40M 43.20M 43.28M
D/E Ratio 0.29 0.25 0.27
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -10,041,478 -10,799,684 -11,152,703
Free Cash Flow -6,132,912 -6,792,749 -5,207,622